Sclerostin
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. One potential new agent is monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis.
Saved in:
| Main Author: | Stuart L. Silverman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Journal of Osteoporosis |
| Online Access: | http://dx.doi.org/10.4061/2010/941419 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sclerostin levels in patients with acromegaly
by: Arnika Wydra, et al.
Published: (2025-08-01) -
Role of sclerostin in mastocytosis bone disease
by: Aneta Szudy-Szczyrek, et al.
Published: (2025-01-01) -
Sclerostin and its role in the regulation of bone metabolism
by: Irina Stepanovna Dydykina, et al.
Published: (2013-06-01) -
Sclerostin as a new target of diabetes-induced osteoporosis
by: Yanhua Li, et al.
Published: (2024-12-01) -
Serum sclerostin in vascular calcification in CKD: a meta-analysis
by: Yan Lin, et al.
Published: (2023-12-01)